Radiofrequency Ablation of Renal Tumors: Four-Year Follow-Up Results in 47 Patients.
10.3348/kjr.2012.13.5.625
- Author:
Soo Dong KIM
1
;
Seong Guk YOON
;
Gyung Tak SUNG
Author Information
1. Department of Urology, Dong-A University College of Medicine, Busan 602-714, Korea. sunggt@dau.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Radiofrequency ablation;
Kidney tumors;
Minimally invasive surgical procedures
- MeSH:
Adult;
Aged;
Catheter Ablation/*methods;
Contrast Media/diagnostic use;
Female;
Follow-Up Studies;
Humans;
Kidney Neoplasms/*surgery;
Laparoscopy;
Magnetic Resonance Imaging;
Male;
Middle Aged;
Neoplasm Recurrence, Local;
Postoperative Complications;
Radiography, Thoracic;
Reoperation;
Retrospective Studies;
Tomography, X-Ray Computed;
Treatment Outcome
- From:Korean Journal of Radiology
2012;13(5):625-633
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To retrospectively evaluate the intermediate results of radiofrequency ablation (RFA) of small renal masses (SRMs). MATERIALS AND METHODS: Percutaneous or laparoscopic RFA was performed on 48 renal tumors in 47 patients. The follow-up studies included a physical examination, chest radiography, creatinine level, and contrast-enhanced CT or MRI. To confirm the pathologic criteria of complete ablation, 35 patients underwent a follow-up biopsy. Recurrence was defined as contrast enhancement on imaging studies after 3 months, lesion growth at subsequent imaging, or viable cancer cells on follow-up biopsy. RESULTS: Technical success was achieved in 43 (89.6%) of 48 renal tumors. The mean tumor size was 2.3 cm and the mean follow-up period was 49.6 months. Repeated RFA was necessary in 5 tumors due to incomplete ablation. The overall complication rate was 35.8%, of which 96.2% were mild complications. Serum creatinine levels at 12 months after RFA did not differ from those before RFA (1.28 vs. 1.36 mg/dL). Four patients were found to have recurrence at various follow-up intervals, and distant metastasis was not found in any cases. CONCLUSION: RFA appears to be a useful treatment for selected patients with SRMs. Our 4-year follow-up results disclose an excellent therapeutic outcome with RFA, while achieving effective local tumor control.
